The official twitter account, promoting the Sputnik V COVID-19 vaccine, tweeted on 20 January 2021 that Russian Direct Investment Fund (RDIF), Russia's sovereign wealth fund, has filed for registration of the COVID-19 Sputnik V in the European Union and expects it to be reviewed in February 2021, Reuters news agency reported on Wednesday.
This moves the vaccine closer to a wider adoption across the globe.
The Sputnik V twitter account said that teams from the vaccine and the European Medical Agency (EMA) held a scientific review of the vaccine on 19 January 2021, adding that the EMA will take a decision on the authorisation of the vaccine based on the reviews.
RDIF's chief, Kirill Dmitriev, had said in an interview at the Reuters Next conference last week that Russia would submit a formal application to the European Union in February 2021 for approval of its Sputnik V COVID-19 vaccine.
Reportedly, the Sputnik V vaccine has already been approved in Argentina, Belarus, Serbia and other countries.
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine
Virbac expands presence in Japan with Sasaeah acquisition
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV